Niagen Bioscience has recently released its first-quarter financial outcomes, showcasing a positive trend in profitability despite increased operational spending. The company, known for its anti-aging supplement range, particularly those linked to NAD+ precursors, confirmed its sales projections for the entire fiscal year. This stability in outlook is largely attributed to expanding digital commerce platforms and newly forged strategic collaborations, even as investments in marketing and administrative functions see an uptick.
For the initial quarter, Niagen Bioscience recorded a 3% year-over-year rise in net sales, achieving $31.5 million. When excluding the impact of a divested segment, the adjusted sales growth stood at 5%. Concurrently, net income saw a notable increase, climbing to $6.3 million from $5.1 million in the corresponding period last year. This improved profitability comes even as operating expenses escalated by 26%, reaching $18.4 million, due to intensified advertising campaigns, research and development activities, and broader commercial outreach.
The company, established in 1999, specializes in supplements that aid the body in producing NAD+, a crucial coenzyme whose levels typically decrease with age. Their flagship product, Tru Niagen, which contains nicotinamide riboside, has successfully navigated FDA safety assessments, though it is not marketed as a treatment or preventative measure for diseases. In recent developments, Niagen has ventured into a clinician-led telehealth platform for at-home injection kits and expanded its product line into skincare with its Nanocloud topical offerings.
Looking ahead, Niagen Bioscience continues to anticipate a 10%-15% increase in full-year net sales, excluding revenues from its divested Analytical Reference Standards and Services division. This projection is underpinned by continued growth in e-commerce and the benefits reaped from strategic partnerships. However, the company has revised its forecast for general and administrative expenses, now expecting an increase of $3 million to $4 million, slightly less than the previously projected $4 million to $5 million. This adjustment accounts for elevated sales and marketing expenditures aimed at customer acquisition and the introduction of new product verticals. Despite a 20% year-to-date decline in its stock value, shares saw a modest recovery, gaining approximately 3% to reach $5 during Wednesday's trading session, reflecting a positive short-term price momentum according to market analyses.
In summary, Niagen Bioscience demonstrates financial resilience with increased first-quarter sales and profit, maintaining a confident outlook for its annual performance. The company's strategic focus on e-commerce, new partnerships, and product innovation, including a telehealth platform and skincare line, positions it for continued growth in the competitive anti-aging supplement market. Despite rising operational costs, these efforts underscore the company's commitment to expanding its market presence and product offerings.